...
search icon
onc-img

BeiGene, Ltd. Share Price

ONC
NSQ
$301.12
+$8.18
(2.79%)
1D
Industry: Biotechnology Sector: Health Care

BeiGene, Ltd. Analyst Forecast

BeiGene, Ltd. Share Price Chart

BeiGene, Ltd. Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$32.42B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
552.717
Volume info-icon
This is the total number of shares traded during the most recent trading day.
298.13K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.52
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$196.45 L
$385.22 H
$301.12

About BeiGene, Ltd., Common Stock

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland. more

Industry: BiotechnologySector: Health Care

BeiGene, Ltd. Stock Returns

Time FrameONCSectorS&P500
1-Week Return-5.01%-3.93%-0.67%
1-Month Return-14.92%-2.41%-1.33%
3-Month Return-7.77%1.64%-0.29%
6-Month Return-13.08%11.65%5.08%
1-Year Return17.18%3.11%19.01%
3-Year Return26.18%19.21%68.62%
5-Year Return2.18%36.52%78.6%
10-Year Return910.81%126.5%240.69%

BeiGene, Ltd. Financials

Dec '21Dec '22Dec '23Dec '24Dec '255YR TREND
Total Revenue1.18B1.42B2.46B3.81B5.34B[{"date":"2021-12-31","value":22.02,"profit":true},{"date":"2022-12-31","value":26.5,"profit":true},{"date":"2023-12-31","value":46.02,"profit":true},{"date":"2024-12-31","value":71.31,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Cost of Revenue164.91M286.48M379.92M594.09M668.54M[{"date":"2021-12-31","value":24.67,"profit":true},{"date":"2022-12-31","value":42.85,"profit":true},{"date":"2023-12-31","value":56.83,"profit":true},{"date":"2024-12-31","value":88.86,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Gross Profit1.01B1.13B2.08B3.22B4.67B[{"date":"2021-12-31","value":21.64,"profit":true},{"date":"2022-12-31","value":24.16,"profit":true},{"date":"2023-12-31","value":44.47,"profit":true},{"date":"2024-12-31","value":68.8,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Gross Margin85.98%79.77%84.55%84.41%87.49%[{"date":"2021-12-31","value":98.28,"profit":true},{"date":"2022-12-31","value":91.18,"profit":true},{"date":"2023-12-31","value":96.64,"profit":true},{"date":"2024-12-31","value":96.48,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Operating Expenses2.45B2.92B3.29B3.78B4.23B[{"date":"2021-12-31","value":57.96,"profit":true},{"date":"2022-12-31","value":69.05,"profit":true},{"date":"2023-12-31","value":77.75,"profit":true},{"date":"2024-12-31","value":89.52,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Operating Income(1.44B)(1.79B)(1.21B)(568.20M)447.14M[{"date":"2021-12-31","value":-321.77,"profit":false},{"date":"2022-12-31","value":-400.25,"profit":false},{"date":"2023-12-31","value":-270.1,"profit":false},{"date":"2024-12-31","value":-127.08,"profit":false},{"date":"2025-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense(15.61M)(118.89M)455.91M83.03M-[{"date":"2021-12-31","value":-3.42,"profit":false},{"date":"2022-12-31","value":-26.08,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":18.21,"profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Pre-Tax Income(1.44B)(1.96B)(825.84M)(533.00M)416.85M[{"date":"2021-12-31","value":-345.11,"profit":false},{"date":"2022-12-31","value":-470.44,"profit":false},{"date":"2023-12-31","value":-198.11,"profit":false},{"date":"2024-12-31","value":-127.86,"profit":false},{"date":"2025-12-31","value":100,"profit":true}]
Income Taxes19.23M42.78M55.87M111.78M129.92M[{"date":"2021-12-31","value":14.8,"profit":true},{"date":"2022-12-31","value":32.93,"profit":true},{"date":"2023-12-31","value":43,"profit":true},{"date":"2024-12-31","value":86.04,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Income After Taxes(1.46B)(2.00B)(881.71M)(644.79M)-[{"date":"2021-12-31","value":-145781600000,"profit":false},{"date":"2022-12-31","value":-200381500000,"profit":false},{"date":"2023-12-31","value":-88170800000,"profit":false},{"date":"2024-12-31","value":-64478600000,"profit":false},{"date":"2025-12-31","value":"-","profit":true}]
Income From Continuous Operations(1.46B)(2.00B)(881.71M)(644.79M)-[{"date":"2021-12-31","value":-145781600000,"profit":false},{"date":"2022-12-31","value":-200381500000,"profit":false},{"date":"2023-12-31","value":-88170800000,"profit":false},{"date":"2024-12-31","value":-64478600000,"profit":false},{"date":"2025-12-31","value":"-","profit":true}]
Income From Discontinued Operations-----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Net Income(1.46B)(2.00B)(881.71M)(644.79M)286.93M[{"date":"2021-12-31","value":-508.07,"profit":false},{"date":"2022-12-31","value":-698.36,"profit":false},{"date":"2023-12-31","value":-307.29,"profit":false},{"date":"2024-12-31","value":-224.72,"profit":false},{"date":"2025-12-31","value":100,"profit":true}]
EPS (Diluted)(15.16)(19.48)(5.14)(5.08)4.15[{"date":"2021-12-31","value":-365.3,"profit":false},{"date":"2022-12-31","value":-469.4,"profit":false},{"date":"2023-12-31","value":-123.86,"profit":false},{"date":"2024-12-31","value":-122.41,"profit":false},{"date":"2025-12-31","value":100,"profit":true}]

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top